Facebook Instagram X-twitter Linkedin

ACE-031-1mg

Table of Contents

  • Quickstart Highlights

ACE-031-1mg protocols center on this recombinant fusion protein designed to inhibit myostatin and related ligands (such as activin A), which are known regulators of muscle growth. By blocking these pathways, ACE-031 may support increased muscle mass, improved strength, and enhanced recovery. This guide outlines a subcutaneous administration approach tailored to the 1 mg vial format.

  • Reconstitute: Add 1.0 mL bacteriostatic water → 1 mg/mL concentration
  • Typical dosing range: 0.25–1 mg per dose (subcutaneous)
  • Easy measuring: At 1 mg/mL, 1 unit = 0.01 mL = 10 mcg on a U-100 insulin syringe
  • Storage: Lyophilized: store frozen at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 2–4 weeks
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support muscle growth and recovery via myostatin inhibition
  • Schedule: 1–2 injections per week due to longer biological activity
  • Dose Range: 0.25–1 mg per administration
  • Dosing Protocol

Suggested approach for the 1 mg vial format.

  • Start: 0.25–0.5 mg once weekly to assess tolerance
  • Target: 0.5–1 mg once or twice weekly
  • Frequency: 1–2 times per week (subcutaneous)
  • Vial Duration: One 1 mg vial typically lasts 1–2 doses
  • Timing: Flexible; often spaced evenly (e.g., every 3–4 days if twice weekly)
  • Mechanism of Action

ACE-031 is a soluble activin receptor type IIB (ActRIIB) fusion protein that functions as a ligand trap. It binds to circulating myostatin and other related proteins (such as activins), preventing them from interacting with their natural receptors.

Myostatin is a negative regulator of muscle growth—meaning it limits muscle development. By inhibiting this pathway, ACE-031 may remove this restriction, allowing increased muscle protein synthesis, muscle fiber growth, and improved overall muscle mass. This mechanism has been widely studied in preclinical models and early clinical research in muscle-wasting conditions.

  • Potential Benefits & Side Effects

Observations based on preclinical and early-stage research.

Potential Benefits:

  • May significantly increase lean muscle mass
  • May improve strength and physical performance
  • May support faster recovery from training or injury
  • Potential application in muscle-wasting conditions

Possible Side Effects:

  • Fluid retention or mild swelling
  • Injection-site reactions
  • Possible effects on vascular markers observed in early studies
  • Long-term safety not fully established; remains investigational